Summit Therapeutics (NASDAQ:SMMT) Shares Gap Down After Earnings Miss

Summit Therapeutics PLC (NASDAQ:SMMT)’s stock price gapped down prior to trading on Friday following a dissappointing earnings announcement. The stock had previously closed at $14.98, but opened at $13.72. Summit Therapeutics shares last traded at $13.5480, with a volume of 1,571,258 shares trading hands.

The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.01).

Key Headlines Impacting Summit Therapeutics

Here are the key news stories impacting Summit Therapeutics this week:

• Positive Sentiment: Summit said updated overall survival data from the Phase III HARMONi study in non-small cell lung cancer continued to strengthen ivonescimab’s profile, reinforcing the drug’s potential as a meaningful oncology asset. Summit Therapeutics (SMMT) Updates Phase III Survival Data, Is The Stock Still A Bargain?
• Positive Sentiment: Summit also announced a clinical trial collaboration with Arcus Biosciences to evaluate ivonescimab in kidney cancer, expanding the drug’s potential market and adding another late-stage development path. Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
• Positive Sentiment: Investors are also focusing on the FDA-accepted BLA for ivonescimab in EGFR-mutant NSCLC and the upcoming November PDUFA date, which keeps a major regulatory catalyst in view. Summit Therapeutics: ‘Buy’ On Ivonescimab’s November PDUFA And Impressive Partner Data
• Neutral Sentiment: Summit’s Q2 report showed a smaller-than-expected loss, with EPS of -$0.28 versus estimates of -$0.27, a modest miss that is less important than the company’s clinical progress. Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026
• Neutral Sentiment: HC Wainwright reaffirmed its neutral rating on SMMT, suggesting analysts remain cautious even as the stock reacts to pipeline news. Benzinga
• Negative Sentiment: The quarterly EPS result slightly missed expectations, which may temper enthusiasm around the stock despite the stronger drug-development headlines. Summit Therapeutics earnings report and conference call

Analysts Set New Price Targets

Several research firms recently commented on SMMT. Cantor Fitzgerald reiterated an “overweight” rating on shares of Summit Therapeutics in a research note on Friday. Sanford C. Bernstein began coverage on Summit Therapeutics in a research note on Thursday, May 21st. They set an “underperform” rating and a $7.70 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Summit Therapeutics in a report on Friday, July 17th. Guggenheim reduced their target price on Summit Therapeutics from $40.00 to $38.00 and set a “buy” rating for the company in a research note on Friday. Finally, HC Wainwright reissued a “neutral” rating on shares of Summit Therapeutics in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $26.15.

Insider Transactions at Summit Therapeutics

In related news, CEO Robert W. Duggan purchased 3,810,000 shares of Summit Therapeutics stock in a transaction dated Friday, June 12th. The shares were acquired at an average price of $13.12 per share, with a total value of $49,987,200.00. Following the completion of the transaction, the chief executive officer owned 573,883,879 shares of the company’s stock, valued at approximately $7,529,356,492.48. This trade represents a 0.67% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Mahkam Zanganeh purchased 3,810,000 shares of the firm’s stock in a transaction that occurred on Friday, June 12th. The stock was purchased at an average price of $13.12 per share, with a total value of $49,987,200.00. Following the completion of the purchase, the chief executive officer directly owned 573,883,879 shares of the company’s stock, valued at approximately $7,529,356,492.48. This represents a 0.67% increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have purchased 7,870,000 shares of company stock valued at $103,616,900. Insiders own 83.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Tema ETFs LLC raised its position in shares of Summit Therapeutics by 1.3% during the 2nd quarter. Tema ETFs LLC now owns 121,097 shares of the company’s stock valued at $1,764,000 after acquiring an additional 1,566 shares in the last quarter. Handelsbanken Fonder AB boosted its holdings in Summit Therapeutics by 24.4% in the second quarter. Handelsbanken Fonder AB now owns 55,500 shares of the company’s stock worth $809,000 after purchasing an additional 10,900 shares during the period. Parallel Advisors LLC boosted its holdings in Summit Therapeutics by 4,178.0% in the first quarter. Parallel Advisors LLC now owns 2,139 shares of the company’s stock worth $41,000 after purchasing an additional 2,089 shares during the period. Bank of America Corp DE increased its stake in Summit Therapeutics by 25.4% during the first quarter. Bank of America Corp DE now owns 598,692 shares of the company’s stock valued at $11,351,000 after purchasing an additional 121,299 shares during the last quarter. Finally, Royal Bank of Canada increased its stake in Summit Therapeutics by 132.2% during the first quarter. Royal Bank of Canada now owns 7,422 shares of the company’s stock valued at $141,000 after purchasing an additional 4,226 shares during the last quarter. Institutional investors and hedge funds own 4.61% of the company’s stock.

Summit Therapeutics Price Performance

The company has a market capitalization of $10.59 billion, a price-to-earnings ratio of -8.58 and a beta of -1.26. The stock’s fifty day simple moving average is $15.09 and its two-hundred day simple moving average is $16.70.

Summit Therapeutics Company Profile

Summit Therapeutics plc is a clinical‐stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life‐threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies.

Summit’s lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S.